Silver Book Fact

Average Annual Direct Medical Costs Per Person with Parkinson’s Disease

Fact image

Hamilton J, The Michael J. Fox Foundation for Parkinson's Research, Yang W, The Lewin Group, et al. The Economic Burden of Parkinson’s Disease; 2019. Accessed June 11, 2019

Reference

Title
The Economic Burden of Parkinson’s Disease
Publication Date
2019
Authors
Hamilton J, The Michael J. Fox Foundation for Parkinson's Research, Yang W, The Lewin Group, et al.

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Donepezil, a new Alzheimer’s medication, increased prescription costs to $1,000 per patient, however the overall health care costs decreased from $11,947 to $8,056.  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2020 Medicare costs for people with the disease would be…  
  • The U.S. Food and Drug Administration has approved 5 drugs for the treatment of Alzheimer’s disease. These drugs have been found to temporarily slow the worsening of Alzheimer’s symptoms for…  
  • An Alzheimer’s disease treatment breakthrough that slowed progression and began to show its effects in 2015, would reduce Medicaid costs for people with the disease by $14 billion in 2020–from…  
  • A study of Parkinson’s disease treatments found that pramipexole is a cost-effective treatment for early and advanced Parkinson’s disease. The total cost-effectiveness ratio was $8,837/QALY for patients with early Parkinson’s…